Medici: The company has fulfilled its contractual obligations, with Hongxu Biology still owing 557,600 yuan in final payments.

On September 23rd, MediXi issued a statement stating that Hongxu Biotech recently published an article on their WeChat official account "Hongxu Biotech" publicly announcing the lawsuit against the company titled "Hongxu Biotech's statement on filing a lawsuit against MediXi according to the law". The content described by Hongxu Biotech in the article seriously deviates from the objective facts. The core disputes of the lawsuit case, such as the signing of the contract, details of performance, and determination of breach of contract responsibility, are all pending for the people's court to investigate and disclose in accordance with the law. In the statement, MediXi stated that the company has fully and properly fulfilled its contractual obligations, and as of the date of this statement, Hongxu Biotech still owes the company 557,600 RMB in contract balance payment. The company reserves the right to recover through all legal means.